BACKGROUND:Sarpogrelate, a serotonin blocker, has been reported to inhibit the serotonin-induced proliferation of rat aortic smooth muscle cells. The aim of this study was to investigate whether sarpogrelate reduces restenosis after coronary stenting as a result of prevention of intimal hyperplasia. METHODS: We examined 79 patients with stable angina undergoing elective coronary stenting on de novo lesions of native coronary arteries in a prospective, randomized trial. All enrolled patients received aspirin and ticlopidine, and one third of the patients were assigned to receive oral sarpogrelate. RESULTS: Treatment with sarpogrelate in addition to aspirin and ticlopidine caused no major adverse cardiovascular events or hemorrhagic adverse effects during the 6-month follow-up period. The restenosis rate in the group of patients receiving sarpogrelate was 4.3%, which was significantly lower than the 28.6% rate found in the group of patients not receiving sarpogrelate. CONCLUSIONS:Sarpogrelate treatment reduces restenosis after coronary stenting, which suggests that serotonin released from activated platelets may play an important role in stent restenosis.
RCT Entities:
BACKGROUND:Sarpogrelate, a serotonin blocker, has been reported to inhibit the serotonin-induced proliferation of rat aortic smooth muscle cells. The aim of this study was to investigate whether sarpogrelate reduces restenosis after coronary stenting as a result of prevention of intimal hyperplasia. METHODS: We examined 79 patients with stable angina undergoing elective coronary stenting on de novo lesions of native coronary arteries in a prospective, randomized trial. All enrolled patients received aspirin and ticlopidine, and one third of the patients were assigned to receive oral sarpogrelate. RESULTS: Treatment with sarpogrelate in addition to aspirin and ticlopidine caused no major adverse cardiovascular events or hemorrhagic adverse effects during the 6-month follow-up period. The restenosis rate in the group of patients receiving sarpogrelate was 4.3%, which was significantly lower than the 28.6% rate found in the group of patients not receiving sarpogrelate. CONCLUSIONS:Sarpogrelate treatment reduces restenosis after coronary stenting, which suggests that serotonin released from activated platelets may play an important role in stent restenosis.
Authors: Daniel Duerschmied; Ingo Ahrens; Maximilian Mauler; Christoph Brandt; Stefanie Weidner; Christoph Bode; Martin Moser Journal: PLoS One Date: 2012-02-27 Impact factor: 3.240